Pharmacokinetic evaluation of oxaliplatin combined with S-1 (SOX) chemotherapy in a rat model of colorectal cancer with acute kidney injury: predictive renal biomarkers for dose optimisation

References

• Basile DP, Anderson MD, Sutton TA. 2012. Pathophysiology of acute kidney injury. Compr Physiol. 2(2):1303–1353. doi: 10.1002/cphy.c110041.
   PubMed Web of Science ®Google Scholar
• Blanco VE, Hernandorena CV, Scibona P, Belloso W, Musso CG. 2019. Acute kidney injury pharmacokinetic changes and its impact on drug prescription. Healthcare (Basel). 7(1):10. doi:10.3390/healthcare7010010.
   PubMedGoogle Scholar
• Eltzschig HK, Eckle T. 2011. Ischemia and reperfusion–from mechanism to translation. Nat Med. 17(11):1391–1401. doi:10.1038/nm.2507.
   PubMed Web of Science ®Google Scholar
• Fujii T, Uchino S, Takinami M, Bellomo R. 2014. Validation of the kidney disease improving global outcomes criteria for AKI and comparison of three criteria in hospitalized patients. Clin J Am Soc Nephrol. 9(5):848–854. doi:10.2215/CJN.09530913.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T. 2002. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol. 50(1):25–32. doi:10.1007/s00280-002-0457-z.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kobuchi S, Shimizu R, Katsuyama Y. 2018. Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats. Cancer Chemother Pharmacol. 81(1):155–161. doi:10.1007/s00280-017-3485-4.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kobuchi S, Takeda M, Morimoto M. 2020. Effect of intact oxaliplatin in plasma on a cold allodynia after multiple administrations in colorectal cancer model rats. Ann Palliat Med. 9(5):3000–3006. doi:10.21037/apm-20-542.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kobuchi S, Takesada W, Takahashi C. 2019. Assessment of oxaliplatin-induced chronic neuropathy and anticancer efficacy through pharmacokinetic and toxicodynamic evaluation of a rat model of colorectal cancer. Anticancer Res. 39(8):4207–4213. doi:10.21873/anticanres.13581.
   PubMedGoogle Scholar
• Kim TH, Shin S, Shin JC, Bulitta JB, Weon KY, Yoo SD, Park GY, Jeong SW, Kwon DR, Min BS, et al. 2017. Effect of sipjeondaebo-tang on the pharmacokinetics of S-1, an anticancer agent, in rats evaluated by population pharmacokinetic modeling. Molecules. 22(9):1488. doi:10.3390/molecules22091488.
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Okada K, Imoto K, Kuwano S, Takada K. 2013. Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. J Pharm Sci. 102(6):2056–2067. doi:10.1002/jps.23547.
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Shimizu R, Ito Y. 2020. Semi-mechanism-based pharmacokinetic-toxicodynamic model of oxaliplatin-induced acute and chronic neuropathy. Pharmaceutics. 12(2):125. doi:10.3390/pharmaceutics12020125.
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Tsuda M, Okamura M, Nakamura T, Ito Y. 2023. A pharmacokinetic-pharmacodynamic model predicts uracil-tegafur effect on tumor shrinkage and myelosuppression in a colorectal cancer rat model. Anticancer Res. 43(3):1121–1130. doi:10.21873/anticanres.16257.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhong D, Zou H, Chen X. 2010. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 52(4):550–556. doi:10.1016/j.jpba.2010.01.026.
   PubMed Web of Science ®Google Scholar
• Matzke GR, Aronoff GR, Atkinson AJ, Jr Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, et al. 2011. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from kidney disease: improving Global Outcomes (KDIGO). Kidney Int. 80(11):1122–1137. doi:10.1038/ki.2011.322.
   PubMed Web of Science ®Google Scholar
• Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V. 2005. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 144(8):1067–1077. doi:10.1038/sj.bjp.070613.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. 2015. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol. 75(3):495–503. doi:10.1007/s00280-014-2667-6.
   PubMed Web of Science ®Google Scholar
• Onose J, Imai T, Hasumura M, Ueda M, Hirose M. 2003. Rapid induction of colorectal tumors in rats initiated with 1,2-dimethylhydrazine followed by dextran sodium sulfate treatment. Cancer Lett. 198(2):145–152. doi:10.1016/s0304-3835(03)00316-1.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN. 2018. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin J Am Soc Nephrol. 13(8):1254–1263. doi:10.2215/CJN.05150418.
   PubMed Web of Science ®Google Scholar
• Rosner MH, Perazella MA. 2017. Acute kidney injury in patients with cancer. N Engl J Med. 376(18):1770–1781. doi:10.1056/NEJMra1613984.
   PubMed Web of Science ®Google Scholar
• Takayama J, Takaoka M, Matsumura tY. 2008. Acute and chronic renal failure model in rats and mice. Nihon Yakurigaku Zasshi. 131(1):37–42. doi:10.1254/fpj.131.37.
   PubMedGoogle Scholar
• Takeda F, Oda M, Terasaki M, Kubota A, Asada K, Ichimura Y, Kojima H, Saitoh H. 2021. Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury. Drug Metab Pharmacokinet. 40:100411. doi:10.1016/j.dmpk.2021.100411.
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, et al. 2007. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 13(16):4832–4839. doi:10.1158/1078-0432.CCR-07-0475.
   PubMed Web of Science ®Google Scholar
• Thangaraj K, Natesan K, Settu K, Palani M, Govindarasu M, Subborayan V, Vaiyapuri M. 2018. Orientin mitigates 1, 2-dimethylhydrazine induced lipid peroxidation, antioxidant and biotransforming bacterial enzyme alterations in experimental rats. J Cancer Res Ther. 14(6):1379–1388. doi:10.4103/jcrt.JCRT_1363_16.
   PubMed Web of Science ®Google Scholar
• Tokunaga A, Miyamoto H, Fumoto S, Nishida K. 2019. Effect of renal ischaemia/reperfusion-induced acute kidney injury on pharmacokinetics of midazolam in rats. J Pharm Pharmacol. 71(12):1792–1799. doi:10.1111/jphp.13167.
   PubMed Web of Science ®Google Scholar
• Wang BY, Li QX, Li J, Xie XF, Ao Y, Ai YX. 2009. Hepatotoxicity and gene expression down-regulation of CYP isozymes caused by renal ischemia/reperfusion in the rat. Exp Toxicol Pathol. 61(2):169–176. doi:10.1016/j.etp.2008.12.010.
   PubMedGoogle Scholar
• Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. 2020. Relationship between renal function and the incidence of adverse events in patients with colorectal cancer receiving oxaliplatin. Anticancer Res. 40(1):299–304. doi:10.21873/anticanres.13953.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, et al. 2013. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 14(13):1278–1286. doi:10.1016/S1470-2045(13)70490-X.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Inui K. 2011. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 81(5):563–568. doi:10.1016/j.bcp.2010.11.016.
   PubMed Web of Science ®Google Scholar
• Zhuang ZX, Zhu H, Wang J, Zhu MG, Wang H, Pu WY, Bian HH, Chen L, Zhang H. 2013. Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients. Acta Pharmacol Sin. 34(4):570–580. doi:10.1038/aps.2012.169.
   PubMed Web of Science ®Google Scholar
• Zuk A, Bonventre JV. 2016. Acute kidney injury. Annu Rev Med. 67(1):293–307. doi:10.1146/annurev-med-050214-013407.
   PubMed Web of Science ®Google Scholar